CareRx (CRRX) Investor presentation summary
Event summary combining transcript, slides, and related documents.
Investor presentation summary
21 Sep, 2026Market opportunity and demand
One in five Canadians are aged 65 or older, with seniors consuming about 40% of prescription drugs and 25% of OTC drugs.
Over 500,000 congregate care beds exist in Canada, forecasted to double in 15 years as the over-65 population grows by 1.5 million by 2031.
Spending on senior care is projected to rise from $29.9 billion in 2021 to $58.5 billion by 2031.
Ontario plans to build 58,000 new or upgraded long-term care beds by 2028.
Business model and service offering
Specializes in pharmacy services for seniors housing communities, focusing on high-touch, same-day delivery and complex medication management.
Operates a purpose-built model distinct from retail pharmacy, tailored for long-term care (LTC) residents.
Delivers integrated clinical, operational, and distribution solutions, promoting efficiency and strong partnerships with LTC operators.
Maintains stable, long-term contracts (5+ years) with direct government and insurance payments, ensuring recurring revenue.
Growth strategy and performance
Serviced approximately 92,000 beds as of June 30, 2026, tripling since 2020.
Growth driven by organic bed wins, new home construction, and accretive M&A in a fragmented market.
Q2 2026 revenue was $93.6M with adjusted EBITDA of $8.0M and an 8.6% margin.
Adjusted EBITDA margin and EBITDA per bed have steadily increased, reflecting operational efficiencies.
Capital priorities include investing for growth, regular dividends, and opportunistic share repurchases.
Latest events from CareRx
- Revenue and EBITDA stable; 3,000-bed contract win and dividend hike drive growth outlook.CRRX
Q2 2026 - Revenue, EBITDA, and margins rose; Ontario funding changes may reduce 2026 fees.CRRX
Q1 2026 - Rapidly growing senior care pharmacy with strong financials and stable, recurring revenue.CRRX
Investor presentation - Strong revenue, margin, and net income growth, plus new dividends and share buybacks.CRRX
Q4 2025 - Q2 2025 saw $91.4M revenue, $8.0M EBITDA, $0.6M net income, and strong growth prospects.CRRX
Q2 2025 - Adjusted EBITDA rose to $7.8M with margin and net loss improving; growth outlook remains strong.CRRX
Q3 2024 - Q2 2024 revenue was $92M, adjusted EBITDA rose to $7.5M, and margins improved to 8.2%.CRRX
Q2 2024 - Stable revenue, margin gains, and new growth initiatives drive improved profitability.CRRX
Q1 2025 - Revenue and EBITDA grew, debt fell by CAD 21.8M, and operational efficiency improved.CRRX
Q4 2024